These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 28800947)

  • 21. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.
    Monti S; Águeda AF; Luqmani RA; Buttgereit F; Cid M; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B
    RMD Open; 2019; 5(2):e001003. PubMed ID: 31673411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and tolerance of tocilizumab for corticosteroid sparing in giant cell arteritis and aortitis: Experience of Nimes University Hospital about eleven patients].
    Broner J; Arnaud E
    Rev Med Interne; 2018 Feb; 39(2):78-83. PubMed ID: 29221884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Giant-cell arteritis pathogenesis].
    Samson M; Bonnotte B
    Presse Med; 2012 Oct; 41(10):937-47. PubMed ID: 22902103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets.
    Koster MJ; Warrington KJ
    BMC Rheumatol; 2017; 1():2. PubMed ID: 30886946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Therapeutic Approaches to Large-Vessel Vasculitis.
    Kaymakci MS; Warrington KJ; Kermani TA
    Annu Rev Med; 2024 Jan; 75():427-442. PubMed ID: 37683286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
    Yoshifuji H
    Mod Rheumatol; 2019 Mar; 29(2):287-293. PubMed ID: 30427262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment.
    Nordborg E; Nordborg C
    Rheumatology (Oxford); 2003 Mar; 42(3):413-21. PubMed ID: 12626790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [How to manage giant cell arteritis].
    Allali D; Blondon M; Roux-Lombard P; Spoerl D
    Rev Med Suisse; 2020 Jan; 16(676-7):12-15. PubMed ID: 31961075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Giant cell arteritis and innovative treatments.
    Costanzo G; Ledda AG; Sambugaro G
    Curr Opin Allergy Clin Immunol; 2023 Aug; 23(4):327-333. PubMed ID: 37357797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic treatment of large-vessel vasculitides.
    Schäfer VS; Zwerina J
    Curr Opin Rheumatol; 2012 Jan; 24(1):31-7. PubMed ID: 22089099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Giant cell arteritis.
    Pepper K
    Postgrad Med; 2023 Jan; 135(sup1):22-32. PubMed ID: 37021621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenesis of giant cell arteritis: new insight into the implication of CD161+ T cells.
    Samson M; Audia S; Martin L; Janikashvili N; Bonnotte B
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S65-73. PubMed ID: 23663684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis.
    Jogimahanti AV; Kini AT; Irwin LE; Lee AG
    J Neuroophthalmol; 2021 Sep; 41(3):342-350. PubMed ID: 34415267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice.
    Paroli M; Caccavale R; Accapezzato D
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.
    Vinicki JP; García-Vicuña R; Arredondo M; López-Bote JP; García-Vadillo JA; Castañeda S; Álvaro-Gracia JM
    Reumatol Clin; 2017; 13(4):210-213. PubMed ID: 27499427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab for the treatment of giant cell arteritis.
    Schirmer M; Muratore F; Salvarani C
    Expert Rev Clin Immunol; 2018 May; 14(5):339-349. PubMed ID: 29676602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current management of giant cell arteritis and its complications.
    Galli E; Muratore F; Warrington KJ
    Curr Opin Rheumatol; 2024 Sep; 36(5):344-350. PubMed ID: 38920090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic approach to giant cell arteritis.
    Masson C
    Joint Bone Spine; 2012 May; 79(3):219-27. PubMed ID: 22119350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index.
    Berti A; Cornec D; Medina Inojosa JR; Matteson EL; Murad MH
    Semin Arthritis Rheum; 2018 Aug; 48(1):77-82. PubMed ID: 29496228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry.
    Alibaz-Öner F; Kelesoglu B; Balci MA; Yardimci GK; Armağan B; Kiliç L; Karakaş Ö; Erden A; Yasar Bilge S; Kardaş RC; Küçük H; Zengin O; Tasci M; Kocaer SB; Yavuz S; Dogru A; Şahin M; Bayindir O; Sevik G; Ertürk Z; Alpay-Kanitez N; Gogebakan H; Tezcan ME; Oksuz MF; Cefle A; Kucuksahin O; Yazici A; Kasapoglu E; Bes C; Unal AU; Dalkiliç E; Yildirim Çetin G; Aksu K; Keser G; Onen F; Çobankara V; Kisacik B; Onat AM; Öztürk MA; Kaşifoğlu T; Omma A; Karadag O; Ates A; Direskeneli H
    Clin Exp Rheumatol; 2024 Apr; 42(4):816-821. PubMed ID: 37976117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.